A.R.T. Advisors’s ImmunityBio IBRX Stock Holding History

A.R.T. Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-11,327	Closed	-$43K	–	494
2019 Q4	$43K	Sell	11,327 -3,251	-22%	-$5.53K	﹤0.01%	1256
2019 Q3	$18K	Buy	+14,578	New	+$18.1K	﹤0.01%	1371
2019 Q2	–	Sell	-16,038	Closed	-$25K	–	1480
2019 Q1	$25K	Buy	+16,038	New	+$20.1K	﹤0.01%	1247
2018 Q2	–	Sell	-30,819	Closed	-$119K	–	1577
2018 Q1	$119K	Buy	+30,819	New	+$135K	﹤0.01%	1340
2017 Q4	–	Sell	-28,244	Closed	-$154K	–	1507
2017 Q3	$154K	Buy	+28,244	New	+$174K	0.01%	1173
2017 Q2	–	Sell	-30,277	Closed	-$107K	–	1543
2017 Q1	$107K	Buy	30,277 +8,577	+40%	+$42.4K	﹤0.01%	1257
2016 Q4	$124K	Buy	+21,700	New	+$145K	0.01%	1124
2016 Q3	–	Sell	-33,118	Closed	-$205K	–	870
2016 Q2	$205K	Buy	+33,118	New	+$257K	0.01%	1102

Other funds holding IBRX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

A.R.T. Advisors's IBRX Position: Q1 2020 in Review

A.R.T. Advisors sold out of ImmunityBio (IBRX) in Q1 2020, closing a stake of 11,327 shares — an estimated $43K sold.

A.R.T. Advisors first reported a position in IBRX in Q2 2016 and held it in 8 quarters. The position peaked at $205K in Q2 2016. 49 funds tracked by Wall St. Rank hold IBRX as of Q1 2020.

A.R.T. Advisors reported no remaining ImmunityBio position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 11,327 ImmunityBio shares in Q1 2020, an estimated $43K.
A.R.T. Advisors first reported a position in ImmunityBio in Q2 2016 and held it in 8 quarters.
A.R.T. Advisors's ImmunityBio position peaked at $205K in Q2 2016.
49 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.